Special Issue "Exploring Inflammation in Cancers"

Quicklinks

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 May 2011)

Special Issue Editor

Guest Editor
Prof. Dr. Masanobu Oshima
Division of Genetics, Cancer Research Institute, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
E-Mail: oshimam@staff.kanazawa-u.ac.jp
Phone: +81-76-264-6760
Fax: +81-76-234-4519
Interests: cancer genetics; molecular pathology of gastrointestinal cancers; cancer stem cell and Wnt signaling

Special Issue Information

Dear Colleagues,

Epidemiological studies have shown that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of cancer development. NSAIDs exert their anti-inflammatory activity through the inhibition of cyclooxygenase-2 (COX-2), resulting in suppression of prostaglandin E2 (PGE2) biosynthesis. Consistently, genetic studies using mouse models have demonstrated that a proinflammatory prostaglandin PGE2 plays an essential role in gastrointestinal cancer development through induction of angiogenesis or suppression of tumor immunity. On the other hand, NF-kB and Stat3 are two major transcription factors in the inflammatory response, which are activated by TNF-a and IL-6, respectively. It has been shown that activation of both NF-kB and Stat3 is required for colitis-associated cancer development in mouse models through inhibition of apoptosis and acceleration of cell proliferation. These results, taken together, indicate that inflammatory signaling networks promote tumor development through multiple pathways. Moreover, recent studies have also indicated that inflammation causes tumor initiation by induction of epigenetic or genetic alterations, and malignant progression through remodeling the metastatic microenvironment. Accordingly, it is possible that targeting inflammation is an effective therapeutic strategy against cancer initiation, promotion and progression. This special issue on “Exploring Inflammation in Cancers” will include original research articles and review papers in the field of inflammation and cancer, including, but not limited to, infection-associated cancer (H. pylori, HCV etc.), cytokine/chemokine signaling in cancer development, innate immunity and acquired immunity (Th1, Th2 or Th17) in cancer development, tumor-associated macrophages (TAMs) in tumorigenesis, and inflammation and epigenetics. Thank you for your collaboration.

Prof. Dr. Masanobu Oshima
Guest Editor

Keywords

  • inflammation
  • COX-2
  • PGE2
  • TNF-alpha
  • NF-kappa B
  • Stat3
  • tumor-associated macrophages
  • colitis-associated cancer
  • innate immunity

Published Papers (10 papers)

Cancers 2011, 3(4), 3894-3908; doi:10.3390/cancers3043894
Received: 13 September 2011; in revised form: 7 October 2011 / Accepted: 9 October 2011 / Published: 14 October 2011
Show/Hide Abstract | Download PDF Full-text (231 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(4), 3740-3761; doi:10.3390/cancers3043740
Received: 31 August 2011; in revised form: 15 September 2011 / Accepted: 19 September 2011 / Published: 28 September 2011
Show/Hide Abstract | Download PDF Full-text (1493 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(4), 3726-3739; doi:10.3390/cancers3043726
Received: 13 September 2011; in revised form: 20 September 2011 / Accepted: 22 September 2011 / Published: 28 September 2011
Show/Hide Abstract | Download PDF Full-text (1757 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(3), 3206-3224; doi:10.3390/cancers3033206
Received: 17 May 2011; in revised form: 2 August 2011 / Accepted: 4 August 2011 / Published: 10 August 2011
Show/Hide Abstract | Download PDF Full-text (890 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(3), 3189-3205; doi:10.3390/cancers3033189
Received: 4 July 2011; in revised form: 28 July 2011 / Accepted: 4 August 2011 / Published: 9 August 2011
Show/Hide Abstract | Download PDF Full-text (670 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(3), 3156-3168; doi:10.3390/cancers3033156
Received: 10 June 2011; in revised form: 2 August 2011 / Accepted: 4 August 2011 / Published: 8 August 2011
Show/Hide Abstract | Download PDF Full-text (390 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(3), 3104-3113; doi:10.3390/cancers3033104
Received: 9 June 2011; in revised form: 25 July 2011 / Accepted: 26 July 2011 / Published: 2 August 2011
Show/Hide Abstract | Download PDF Full-text (832 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(3), 3018-3028; doi:10.3390/cancers3033018
Received: 3 June 2011; in revised form: 12 July 2011 / Accepted: 19 July 2011 / Published: 25 July 2011
Show/Hide Abstract | Download PDF Full-text (1164 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(3), 2811-2826; doi:10.3390/cancers3032811
Received: 23 May 2011; in revised form: 17 June 2011 / Accepted: 21 June 2011 / Published: 27 June 2011
Show/Hide Abstract | Download PDF Full-text (512 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 2750-2766; doi:10.3390/cancers3022750
Received: 13 May 2011; in revised form: 9 June 2011 / Accepted: 14 June 2011 / Published: 22 June 2011
Show/Hide Abstract | Download PDF Full-text (297 KB) | View HTML Full-text | Download XML Full-text

Last update: 25 February 2014

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert